Titan Medical Reveals New Robotic Surgical System Brand Identity and Updated Corporate Brand Identity
September 21 2020 - 7:00AM
Business Wire
Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD)
(Nasdaq:TMDI), a medical device company focused on the design
and development of robotic surgical technologies, announced today
the launch of a new name and brand identity for its robotic
surgical system under development, the Enos™ robotic single access
surgical system.
During the coming weeks, the Company will gradually transition
to the new Enos brand identity, including on its website and in
presentations and other corporate material. Along with the change
to the identity of its surgical system, the Company will transition
to an updated corporate brand identity that, while retaining the
Titan Medical name, complements the Enos robotic single access
surgical system.
Enos, translated from the Greek language, has the meaning “of
one,” which aligns well with Titan’s commitment to single access
surgery. Working with an industry-leading branding team, the
Company determined that while it should retain its corporate name
as a valuable asset, the use of “SPORT” as an identity for its
surgical system did not accurately reflect the Company’s values and
beliefs and the uniqueness of its technology.
“We are excited to share the renaming and branding of our single
access surgical system,” said David McNally, President and CEO of
Titan Medical Inc. “While our technology focus remains the same,
the Enos identity better reflects the Company’s belief that a
single incision and simplified approach to surgical procedures is
better for everyone, bringing immense potential for expanding
utilization and the elevation of the standard of care for patients
around the world.
“The new brand identities demonstrate the evolution of Titan
Medical and what we are seeking to accomplish in the robotic
assisted surgery space; to become the new standard of care in
robotic single access surgery,” McNally added. “As we have
successfully leveraged our in-depth robotic surgery expertise,
technology and intellectual property to establish strategic
relationships, and as we have recommenced the development of our
surgical system, we believe now is the appropriate time to launch
the new brand identities.”
About Titan
Titan Medical Inc. is focused on robotic-assisted technologies
for application in minimally invasive surgery (“MIS”). Enos, by
Titan Medical, is being developed to become the new standard of
care in robotic single access surgery, and comprises a
surgeon-controlled patient cart that includes a dual-view camera
system with 3D and 2D high-definition vision systems and
multi-articulating instruments for performing MIS procedures, and a
surgeon workstation that provides an ergonomic interface to the MIS
procedure performed through the patient cart. With the Enos system,
Titan intends to initially pursue gynecologic surgical
indications.
For more information, visit www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws. Such
statements reflect the current expectations of management of the
Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Report on Form 20F dated March 30, 2020 (which may be viewed at
www.sedar.com and at www.sec.gov). Should one or more of these
risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. These factors should be considered
carefully, and prospective investors should not place undue
reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable
assumptions, the Company cannot assure prospective investors that
actual results, performance or achievements will be consistent with
these forward-looking statements. Except as required by law, the
Company expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200921005103/en/
Stephen Randall Chief Financial Officer +1-416-548-7522
stephen@titanmedicalinc.com
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Apr 2024 to May 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From May 2023 to May 2024